| Michelle Cathlea Atterbury, LCSW, LMSW | |
|
1160 Lincoln Ave, Fennimore, WI 53809-1746 | |
| (608) 822-5052 | |
| (608) 822-0131 |
| Full Name | Michelle Cathlea Atterbury |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1160 Lincoln Ave, Fennimore, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578127247 | NPI | - | NPPES |
| 30762 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 10105 (Wisconsin) | Primary |
| 104100000X | Social Worker | 131356-121 (Wisconsin) | Secondary |
| Entity Name | Gtn Fennimore Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306251640 PECOS PAC ID: 3072738335 Enrollment ID: O20140701000695 |
News Archive
The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.
Chronic kidney disease (CKD) can significantly lessen patients' quality of life, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Certain types of patients - women, diabetics, and those with a history of heart complications - are most affected.
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.
Pepex Biomedical, Inc. has unveiled development of a next generation solution for insulin dependent diabetics which will combine regular glucose monitoring and insulin delivery for diabetes sufferers worldwide. The company is developing a complete product line of multi-function meters which allow simple testing of blood glucose levels and insulin delivery, appropriate to each glucose level measurement, all contained in a single, palm-sized unit. These meters provide anytime, anywhere tracking and treatment of diabetes.
BK Medical, a wholly owned subsidiary of Analogic Corporation, launches its new, full-featured ultrasound system, the Pro Focus UltraView, for the surgical and urological ultrasound markets.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michelle Cathlea Atterbury, LCSW, LMSW 710 2nd St, Bloomington, WI 53804-9650 Ph: (608) 379-3373 | Michelle Cathlea Atterbury, LCSW, LMSW 1160 Lincoln Ave, Fennimore, WI 53809-1746 Ph: (608) 822-5052 |
News Archive
The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.
Chronic kidney disease (CKD) can significantly lessen patients' quality of life, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Certain types of patients - women, diabetics, and those with a history of heart complications - are most affected.
Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company and Pfizer Inc., was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant non-major bleeding in patients treated with apixaban compared with those treated with enoxaparin.
Pepex Biomedical, Inc. has unveiled development of a next generation solution for insulin dependent diabetics which will combine regular glucose monitoring and insulin delivery for diabetes sufferers worldwide. The company is developing a complete product line of multi-function meters which allow simple testing of blood glucose levels and insulin delivery, appropriate to each glucose level measurement, all contained in a single, palm-sized unit. These meters provide anytime, anywhere tracking and treatment of diabetes.
BK Medical, a wholly owned subsidiary of Analogic Corporation, launches its new, full-featured ultrasound system, the Pro Focus UltraView, for the surgical and urological ultrasound markets.
› Verified 4 days ago
Nicole M Kaiser, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1160 Lincoln Ave, Fennimore, WI 53809 Phone: 608-822-5052 Fax: 608-776-4914 |